Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Pierre van der Bruggen

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Physiology

Genes & Molecular Sequences

Amino Acid Sequence

Concepts & Ideas

Molecular Sequence Data

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
François Violaine; Ottaviani Sabrina; Renkvist Nicolina; Stockis Julie; Schuler Gerold; Thielemans Kris; Colau Didier; Marchand Marie; Boon Thierry; Lucas Sophie; van der Bruggen Pierre
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
Bonehill Aude; Van Nuffel An M T; Corthals Jurgen; Tuyaerts Sandra; Heirman Carlo; François Violaine; Colau Didier; van der Bruggen Pierre; Neyns Bart; Thielemans Kris
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Stockis Julie; Fink Wolfram; François Violaine; Connerotte Thierry; de Smet Charles; Knoops Laurent; van der Bruggen Pierre; Boon Thierry; Coulie Pierre G; Lucas Sophie
Comparison of stable human Treg and Th clones by transcriptional profiling.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Pierre van der Bruggen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: François Violaine; Ottaviani Sabrina; Renkvist Nicolina; Stockis Julie; Schuler Gerold; Thielemans Kris; Colau Didier; Marchand Marie; Boon Thierry; Lucas Sophie; van der Bruggen Pierre
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
Cancer research 2009;69(10):4335-45.
2009: Bonehill Aude; Van Nuffel An M T; Corthals Jurgen; Tuyaerts Sandra; Heirman Carlo; François Violaine; Colau Didier; van der Bruggen Pierre; Neyns Bart; Thielemans Kris
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3366-75.
2009: Stockis Julie; Fink Wolfram; François Violaine; Connerotte Thierry; de Smet Charles; Knoops Laurent; van der Bruggen Pierre; Boon Thierry; Coulie Pierre G; Lucas Sophie
Comparison of stable human Treg and Th clones by transcriptional profiling.
European journal of immunology 2009;39(3):869-82.
2008: Baurain Jean-François; Van der Bruggen Pierre; Van den Eynde Benoît J; Coulie Pierre G; Van Baren Nicolas
[General principles and first clinical trials of therapeutic vaccines against cancer]
Bulletin du cancer 2008;95(3):327-35.
2008: Demotte Nathalie; Stroobant Vincent; Courtoy Pierre J; Van Der Smissen Patrick; Colau Didier; Luescher Immanuel F; Hivroz Claire; Nicaise Julie; Squifflet Jean-Luc; Mourad Michel; Godelaine Danièle; Boon Thierry; van der Bruggen Pierre
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.
Immunity 2008;28(3):414-24.
2008: Carrasco Javier; Van Pel Aline; Neyns Bart; Lethé Bernard; Brasseur Francis; Renkvist Nicolina; van der Bruggen Pierre; van Baren Nicolas; Paulus Robert; Thielemans Kris; Boon Thierry; Godelaine Danièle
Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(5):3585-93.
2007: Erfurt Cornelia; Sun Zhaojun; Haendle Ina; Schuler-Thurner Beatrice; Heirman Carlo; Thielemans Kris; van der Bruggen Pierre; Schuler Gerold; Schultz Erwin S
Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):7703-9.
2007: Wang Xiao-Fei; Cohen William M; Castelli Florence A; Almunia Christine; Lethé Bernard; Pouvelle-Moratille Sandra; Munier Gaetan; Charron Dominique; Ménez André; Zarour Hassan M; van der Bruggen Pierre; Busson Marc; Maillère Bernard
Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.
Cancer immunology, immunotherapy : CII 2007;56(6):807-18.
2007: van der Bruggen Pierre; Traversari Catia; Chomez Patrick; Lurquin Christophe; De Plaen Etienne; Van den Eynde Benoît J; Knuth Alexander; Boon Thierry
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(5):2617-21.
2006: Carrasco Javier; Godelaine Danièle; Van Pel Aline; Boon Thierry; van der Bruggen Pierre
CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation.
Blood 2006;108(9):2897-905.
2006: Ottaviani Sabrina; Colau Didier; van der Bruggen Pierre; van der Bruggen Pierre
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
Cancer immunology, immunotherapy : CII 2006;55(7):867-72.
2006: Ottaviani Sabrina; Colau Didier; van der Bruggen Pierre; van der Bruggen Pierre
A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
Cancer immunology, immunotherapy : CII 2006;55(7):867-72.
2006: Sun Zhaojun; Lethé Bernard; Zhang Yi; Russo Vincenzo; Colau Didier; Stroobant Vincent; Boon Thierry; van der Bruggen Pierre
A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.
Cancer immunology, immunotherapy : CII 2006;55(6):644-52.
2006: van der Bruggen Pierre; Van den Eynde Benoît J
Processing and presentation of tumor antigens and vaccination strategies.
Current opinion in immunology 2006;18(1):98-104.
2006: Boon Thierry; Coulie Pierre G; Van den Eynde Benoît J; van der Bruggen Pierre
Human T cell responses against melanoma.
Annual review of immunology 2006;24():175-208.
2005: van Baren Nicolas; Bonnet Marie-Claude; Dréno Brigitte; Khammari Amir; Dorval Thierry; Piperno-Neumann Sophie; Liénard Danielle; Speiser Daniel; Marchand Marie; Brichard Vincent G; Escudier Bernard; Négrier Sylvie; Dietrich Pierre-Yves; Maraninchi Dominique; Osanto Susanne; Meyer Ralf G; Ritter Gerd; Moingeon Philippe; Tartaglia Jim; van der Bruggen Pierre; Coulie Pierre G; Boon Thierry
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):9008-21.
2005: Ottaviani Sabrina; Zhang Yi; Boon Thierry; van der Bruggen Pierre
A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Cancer immunology, immunotherapy : CII 2005;54(12):1214-20.
2005: Kruit Wim H J; van Ojik Heidi H; Brichard Vincent G; Escudier Bernard; Dorval Thierry; Dréno Brigitte; Patel Poulam; van Baren Nicolas; Avril Marie-Françoise; Piperno Sophie; Khammari Amir; Stas Marguerite; Ritter Gerd; Lethé Bernard; Godelaine Danièle; Brasseur Francis; Zhang Yi; van der Bruggen Pierre; Boon Thierry; Eggermont Alexander M M; Marchand Marie
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
International journal of cancer. Journal international du cancer 2005;117(4):596-604.
2005: Michiels A; Tuyaerts S; Bonehill A; Corthals J; Breckpot K; Heirman C; Van Meirvenne S; Dullaers M; Allard S; Brasseur F; van der Bruggen P; Thielemans K
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
Gene therapy 2005;12(9):772-82.
2005: Zhang Yi; Renkvist Nicolina; Sun Zhaojun; Schuler-Thurner Beatrice; Glaichenhaus Nicolas; Schuler Gerold; Boon Thierry; van der Bruggen Pierre; Colau Didier
A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
European journal of immunology 2005;35(4):1066-75.
2005: Zhang Yi; Sun Zhaojun; Nicolay Hugues; Meyer Ralf G; Renkvist Nicolina; Stroobant Vincent; Corthals Jurgen; Carrasco Javier; Eggermont Alexander M M; Marchand Marie; Thielemans Kris; Wölfel Thomas; Boon Thierry; van der Bruggen Pierre
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(4):2404-11.
2004: Lonchay Christophe; van der Bruggen Pierre; Connerotte Thierry; Hanagiri Takeshi; Coulie Pierre; Colau Didier; Lucas Sophie; Van Pel Aline; Thielemans Kris; van Baren Nicolas; Boon Thierry
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14631-8.
2004: Dullaers Melissa; Breckpot Karine; Van Meirvenne Sonja; Bonehill Aude; Tuyaerts Sandra; Michiels Annelies; Straetman Lieven; Heirman Carlo; De Greef Catherine; Van Der Bruggen Pierre; Thielemans Kris
Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;10(4):768-79.
2004: Bonehill Aude; Heirman Carlo; Tuyaerts Sandra; Michiels Annelies; Breckpot Karine; Brasseur Francis; Zhang Yi; Van Der Bruggen Pierre; Thielemans Kris
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(11):6649-57.
2004: Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Tissue antigens 2004;63(5):453-7.
2004: Vigneron Nathalie; Stroobant Vincent; Chapiro Jacques; Ooms Annie; Degiovanni Gérard; Morel Sandra; van der Bruggen Pierre; Boon Thierry; Van den Eynde Benoît J
An antigenic peptide produced by peptide splicing in the proteasome.
Science (New York, N.Y.) 2004;304(5670):587-90.
2004: Breckpot Karine; Heirman Carlo; De Greef Catherine; van der Bruggen Pierre; Thielemans Kris
Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2232-7.
2004: Schultz Erwin S; Schuler-Thurner Beatrice; Stroobant Vincent; Jenne Lars; Berger Thomas G; Thielemanns Kris; van der Bruggen Pierre; Schuler Gerold
Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(2):1304-10.
2003: Vantomme Valérie; Boël Pascale; De Plaen Etienne; Boon Thierry; van der Bruggen Pierre
A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
Cancer immunity : a journal of the Academy of Cancer Immunology 2003;3():17.
2003: Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P
New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Tissue antigens 2003;62(5):426-32.
2003: Bonehill Aude; Heirman Carlo; Tuyaerts Sandra; Michiels Annelies; Zhang Yi; van der Bruggen Pierre; Thielemans Kris
Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Cancer research 2003;63(17):5587-94.
2003: Breckpot Karine; Dullaers Melissa; Bonehill Aude; van Meirvenne Sonja; Heirman Carlo; de Greef Catherine; van der Bruggen Pierre; Thielemans Kris
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.
The journal of gene medicine 2003;5(8):654-67.
2003: Zhang Yi; Chaux Pascal; Stroobant Vincent; Eggermont Alexander M M; Corthals Jurgen; Maillère Bernard; Thielemans Kris; Marchand Marie; Boon Thierry; Van Der Bruggen Pierre
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(1):219-25.
2003: Coulie Pierre G; van der Bruggen Pierre
T-cell responses of vaccinated cancer patients.
Current opinion in immunology 2003;15(2):131-7.
2003: Jacquemin Marc; Vantomme Valérie; Buhot Cécile; Lavend'homme Renaud; Burny Wivine; Demotte Nathalie; Chaux Pascal; Peerlinck Kathelijne; Vermylen Jos; Maillere Bernard; van der Bruggen Pierre; Saint-Remy Jean-Marie
CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.
Blood 2003;101(4):1351-8.
2002: Zhang Y; Stroobant V; Russo V; Boon T; van der Bruggen P
A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes.
Tissue antigens 2002;60(5):365-71.
2002: Van Der Bruggen Pierre; Zhang Yi; Chaux Pascal; Stroobant Vincent; Panichelli Christophe; Schultz Erwin S; Chapiro Jacques; Van Den Eynde Benoît J; Brasseur Francis; Boon Thierry
Tumor-specific shared antigenic peptides recognized by human T cells.
Immunological reviews 2002;188():51-64.
2002: Bilsborough J; Panichelli C; Duffour M-T; Warnier G; Lurquin C; Schultz E S; Thielemans K; Corthals J; Boon T; van der Bruggen P
A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
Tissue antigens 2002;60(1):16-24.
2002: Demotte Nathalie; Colau Didier; Ottaviani Sabrina; Godelaine Danièle; Van Pel Aline; Boon Thierry; van der Bruggen Pierre
A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling.
European journal of immunology 2002;32(6):1688-97.
2002: Schultz Erwin S; Chapiro Jacques; Lurquin Christophe; Claverol Stéphane; Burlet-Schiltz Odile; Warnier Guy; Russo Vincenzo; Morel Sandra; Lévy Frédéric; Boon Thierry; Van den Eynde Benoît J; van der Bruggen Pierre
The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
The Journal of experimental medicine 2002;195(4):391-9.
2001: Chaux P; Lethé B; Van Snick J; Corthals J; Schultz E S; Cambiaso C L; Boon T; van der Bruggen P
A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.
European journal of immunology 2001;31(6):1910-6.
2001: Schultz E S; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P
A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
Tissue antigens 2001;57(2):103-9.
2000: Schultz E S; Lethé B; Cambiaso C L; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Cancer research 2000;60(22):6272-5.
2000: Luiten R M; Demotte N; Tine J; van der Bruggen P
A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
Tissue antigens 2000;56(1):77-81.
2000: Mandruzzato S; Stroobant V; Demotte N; van der Bruggen P
A human CTL recognizes a caspase-8-derived peptide on autologous HLA-B*3503 molecules and two unrelated peptides on allogeneic HLA-B*3501 molecules.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(8):4130-4.
2000: Luiten R; van der Bruggen P
A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
Tissue antigens 2000;55(2):149-52.
1999: Morel S; Ooms A; Van Pel A; Wölfel T; Brichard V G; van der Bruggen P; Van den Eynde B J; Degiovanni G
A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 1999;83(6):755-9.
1999: Duffour M T; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
European journal of immunology 1999;29(10):3329-37.
1999: Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis G R; Boon T; van der Bruggen P
Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(5):2928-36.
1999: De Backer O; Arden K C; Boretti M; Vantomme V; De Smet C; Czekay S; Viars C S; De Plaen E; Brasseur F; Chomez P; Van den Eynde B; Boon T; van der Bruggen P
Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.
Cancer research 1999;59(13):3157-65.
1999: Huang L Q; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(11):6849-54.
1999: Chaux P; Vantomme V; Stroobant V; Thielemans K; Corthals J; Luiten R; Eggermont A M; Boon T; van der Bruggen P
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.
The Journal of experimental medicine 1999;189(5):767-78.
1999: Marchand M; van Baren N; Weynants P; Brichard V; Dréno B; Tessier M H; Rankin E; Parmiani G; Arienti F; Humblet Y; Bourlond A; Vanwijck R; Liénard D; Beauduin M; Dietrich P Y; Russo V; Kerger J; Masucci G; Jäger E; De Greve J; Atzpodien J; Brasseur F; Coulie P G; van der Bruggen P; Boon T
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
International journal of cancer. Journal international du cancer 1999;80(2):219-30.
1998: Van de Craen M; Van Loo G; Declercq W; Schotte P; Van den brande I; Mandruzzato S; van der Bruggen P; Fiers W; Vandenabeele P
Molecular cloning and identification of murine caspase-8.
Journal of molecular biology 1998;284(4):1017-26.
1998: Lee R S; Tartour E; van der Bruggen P; Vantomme V; Joyeux I; Goud B; Fridman W H; Johannes L
Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.
European journal of immunology 1998;28(9):2726-37.
1998: Chaux P; Vantomme V; Coulie P; Boon T; van der Bruggen P
Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.
International journal of cancer. Journal international du cancer 1998;77(4):538-42.
1997: Fisch P; Meuer E; Pende D; Rothenfusser S; Viale O; Kock S; Ferrone S; Fradelizi D; Klein G; Moretta L; Rammensee H G; Boon T; Coulie P; van der Bruggen P
Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity.
European journal of immunology 1997;27(12):3368-79.
1997: Traversari C; Meazza R; Coppolecchia M; Basso S; Verrecchia A; van der Bruggen P; Ardizzoni A; Gaggero A; Ferrini S
IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer.
Gene therapy 1997;4(10):1029-35.
1997: Van den Eynde B J; van der Bruggen P
T cell defined tumor antigens.
Current opinion in immunology 1997;9(5):684-93.
1997: Fleischhauer K; Tanzarella S; Russo V; Sensi M L; van der Bruggen P; Bordignon C; Traversari C
Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(5):2513-21.
1997: Lethé B; van der Bruggen P; Brasseur F; Boon T
MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
Melanoma research 1997;7 Suppl 2():S83-8.
1997: Mandruzzato S; Brasseur F; Andry G; Boon T; van der Bruggen P
A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.
The Journal of experimental medicine 1997;186(5):785-93.
1997: De Plaen E; Lurquin C; Lethé B; van der Bruggen P; Brichard V; Renauld J C; Coulie P; Van Pel A; Boon T
Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.
Methods (San Diego, Calif.) 1997;12(2):125-42.
1997: Coulie P G; Van den Eynde B J; van der Bruggen P; Van Pel A; Boon T
Antigens recognized by T-lymphocytes on human tumours.
Biochemical Society transactions 1997;25(2):544-8.
1996: Farina C; van der Bruggen P; Boël P; Parmiani G; Sensi M
Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens.
International immunology 1996;8(9):1463-6.
1996: Boon T; van der Bruggen P
Human tumor antigens recognized by T lymphocytes.
The Journal of experimental medicine 1996;183(3):725-9.
1996: Viale O; van der Bruggen P; Meuer E; Kunzmann R; Kohler H; Mertelsmann R; Boon T; Fisch P
Recognition by human Vgamma9/Vdelta2 T cells of melanoma cells upon fusion with Daudi cells.
Immunogenetics 1996;45(1):27-34.
1996: Herman J; van der Bruggen P; Luescher I F; Mandruzzato S; Romero P; Thonnard J; Fleischhauer K; Boon T; Coulie P G
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Immunogenetics 1996;43(6):377-83.
1995: Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
Biochemical Society transactions 1995;23(3):681-6.
1995: Van Pel A; van der Bruggen P; Coulie P G; Brichard V G; Lethé B; van den Eynde B; Uyttenhove C; Renauld J C; Boon T
Genes coding for tumor antigens recognized by cytolytic T lymphocytes.
Immunological reviews 1995;145():229-50.
1995: Boël P; Wildmann C; Sensi M L; Brasseur R; Renauld J C; Coulie P; Boon T; van der Bruggen P
BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
Immunity 1995;2(2):167-75.
1994: van der Bruggen P; Bastin J; Gajewski T; Coulie P G; Boël P; De Smet C; Traversari C; Townsend A; Boon T
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
European journal of immunology 1994;24(12):3038-43.
1994: Amar-Costesec A; Godelaine D; Stockert E; van der Bruggen P; Beaufay H; Chen Y T
The tumor protein MAGE-1 is located in the cytosol of human melanoma cells.
Biochemical and biophysical research communications 1994;204(2):710-5.
1994: van der Bruggen P; Szikora J P; Boël P; Wildmann C; Somville M; Sensi M; Boon T
Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
European journal of immunology 1994;24(9):2134-40.
1994: van der Bruggen P
The long-standing quest for tumor rejection antigens.
Clinical immunology and immunopathology 1994;71(3):248-52.
1994: Gaugler B; Van den Eynde B; van der Bruggen P; Romero P; Gaforio J J; De Plaen E; Lethé B; Brasseur F; Boon T
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.
The Journal of experimental medicine 1994;179(3):921-30.
1994: Chen Y T; Stockert E; Chen Y; Garin-Chesa P; Rettig W J; van der Bruggen P; Boon T; Old L J
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(3):1004-8.
1994: De Smet C; Lurquin C; van der Bruggen P; De Plaen E; Brasseur F; Boon T
Sequence and expression pattern of the human MAGE2 gene.
Immunogenetics 1994;39(2):121-9.
1994: Boon T; Cerottini J C; Van den Eynde B; van der Bruggen P; Van Pel A
Tumor antigens recognized by T lymphocytes.
Annual review of immunology 1994;12():337-65.
1994: De Plaen E; Arden K; Traversari C; Gaforio J J; Szikora J P; De Smet C; Brasseur F; van der Bruggen P; Lethé B; Lurquin C
Structure, chromosomal localization, and expression of 12 genes of the MAGE family.
Immunogenetics 1994;40(5):360-9.
1994: Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora J P; De Backer O
Genes coding for tumor-specific rejection antigens.
Cold Spring Harbor symposia on quantitative biology 1994;59():617-22.
1993: Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
Dermatology (Basel, Switzerland) 1993;186(4):278-80.
1992: Traversari C; van der Bruggen P; Luescher I F; Lurquin C; Chomez P; Van Pel A; De Plaen E; Amar-Costesec A; Boon T
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
The Journal of experimental medicine 1992;176(5):1453-7.
1992: van der Bruggen P; Van den Eynde B
Molecular definition of tumor antigens recognized by T lymphocytes.
Current opinion in immunology 1992;4(5):608-12.
1992: Traversari C; van der Bruggen P; Van den Eynde B; Hainaut P; Lemoine C; Ohta N; Old L; Boon T
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes.
Immunogenetics 1992;35(3):145-52.
1992: Boon T; De Plaen E; Lurquin C; Van den Eynde B; van der Bruggen P; Traversari C; Amar-Costesec A; Van Pel A
Identification of tumour rejection antigens recognized by T lymphocytes.
Cancer surveys 1992;13():23-37.
1991: van der Bruggen P; Traversari C; Chomez P; Lurquin C; De Plaen E; Van den Eynde B; Knuth A; Boon T
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
Science (New York, N.Y.) 1991;254(5038):1643-7.
1989: Van den Eynde B; Hainaut P; Hérin M; Knuth A; Lemoine C; Weynants P; van der Bruggen P; Fauchet R; Boon T
Presence on a human melanoma of multiple antigens recognized by autologous CTL.
International journal of cancer. Journal international du cancer 1989;44(4):634-40.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Pierre van der Bruggen

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Physiology

Genes & Molecular Sequences

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Pierre van der Bruggen (preview)

All Publications